19,358 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by World Investment Advisors LLC

World Investment Advisors LLC bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 19,358 shares of the biotechnology company's stock, valued at approximately $2,418,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its position in Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock worth $544,408,000 after acquiring an additional 543,143 shares during the period. Wellington Management Group LLP lifted its position in shares of Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Geode Capital Management LLC boosted its stake in Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock valued at $211,910,000 after purchasing an additional 44,306 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in Sarepta Therapeutics by 9.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company's stock valued at $94,148,000 after buying an additional 63,437 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its position in Sarepta Therapeutics by 6.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company's stock worth $101,858,000 after buying an additional 37,940 shares during the period. Institutional investors own 86.68% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. HC Wainwright cut their price target on Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating for the company in a report on Tuesday, December 3rd. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They issued a "buy" rating and a $165.00 price objective for the company. William Blair upgraded shares of Sarepta Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. StockNews.com lowered shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. Finally, Piper Sandler cut their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $178.71.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 1,636 shares of the company's stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Trading Down 0.6 %

Shares of SRPT traded down $0.76 during trading hours on Friday, hitting $123.71. The company had a trading volume of 730,761 shares, compared to its average volume of 1,223,790. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock's 50 day moving average price is $123.12 and its 200 day moving average price is $131.43. The firm has a market cap of $11.82 billion, a P/E ratio of 98.97 and a beta of 0.77. Sarepta Therapeutics, Inc. has a 52-week low of $89.92 and a 52-week high of $173.25.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.